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Dear Editor,
We would like to thank Kenneth Rolston for his com-
ments regarding our recent Supportive Care in Cancer
article on chronic disseminated candidiasis (CDC) in pa-
tients with hematological malignancies on the behalf of
SEIFEM (Sorveglianza Epidemiologica Infezioni
Fungine in Ematologia) group [1].
We acknowledge the small sample size (N = 20) and
the retrospective nature of the study, which is probably
not enough capable to lead to significant modifications
of the CDC treatment recommendations. However, we
would like to underline some aspects.
First, the guidelines of the Infectious Diseases Society
of America (IDSA) strongly recommend the first line ther-
apy of CDC with lipid formulation amphotericin B (AmB)
3–5 mg/kg daily [2]. Our data suggest that high-dose
(HD) liposomal AmB (5 mg/kg daily) is the better choice
for the treatment of CDC. This is likely due to the fungi-
cide action of HD liposomal AmB in the liver and spleen
derived from better tissue concentrations (target of liposo-
mal formulation: reticuloendothelial system) than that of
triazoles and echinocandins [3]. In addition, the 5 mg/kg
daily dosage for liposomal AmB may be useful for less
susceptible species, such as Candida glabrata and
Candida krusei [2]. On the other hand, in our series, the ma-
jority of patients were receiving triazoles prophylaxis and thus
had an increased risk of developing infection with a fluconazole-
resistant organism [2]. Moreover, according to the IDSA guide-
lines, fluconazole (6 mg/kg daily) should be administered only
for maintenance therapy [2].
Second, 13/20 (65%) patients received diagnosis of
probable CDC according to standard criteria, i.e., an alka-
line phosphatase increase, hepatic and/or splenic nodules
with typical bull’s eye aspect (seen at imaging tools), and
blood cultures positive for Candida spp. (no polymicrobic
sepsis occurred in our series) [4]. Such patients had neg-
ative serum galactomannan monitoring and negative tho-
rax radiological assessments; three cases had a serum β-
D-glucan assay >80 pg/ml (270, 520, and 370 pg/ml, re-
spectively). Altogether, it is very unlikely that these find-
ings may represent infections due to other organisms, par-
ticularly molds. According to the policy of the SEIFEM
group, when clinically indicated, we performed liver bi-
opsy using a Menghini-type automatic fine-cutting needle
(1.2 mm, 18G) under color ultrasound guidance, as al-
ready reported [5, 6]. In fact, the remaining seven patients
underwent a mini-invasive procedure that was well toler-
ated with no discomfort and provided reliable information
regarding liver histology, leading to the definitive diagno-
sis of CDC.
Third, both cases no. 11 and no. 20 died early as a
result of CDC (before the definitive microbiological re-
sults from blood samples); they were receiving empirical
antifungal treatment, respectively, with fluconazole and
itraconazole.
Finally, no liposomal AmB-related toxicity of grade ≥3,
according to the Common Terminology Criteria for Adverse
Events (CTCAE), occurred in our series [7].
* Roberta Della Pepa
roberta.dellapepa@unina.it
1 Department of Clinical Medicine and Surgery, Hematology, Federico
II University, Via Sergio Pansini, 5, 80131 Naples, Italy
2 Institute of Hematology, Università Cattolica del Sacro Cuore,
Rome, Italy
3 Department of Advanced Biomedical Science, Federico II
University, Naples, Italy
Support Care Cancer (2017) 25:1045–1046
DOI 10.1007/s00520-017-3574-2
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Open Access This article is distributed under the terms of the Creative
Commons Attribution-NonCommercial 4.0 International License (http://
creativecommons.org/licenses/by-nc/4.0/), which permits any noncom-
mercial use, distribution, and reproduction in any medium, provided
you give appropriate credit to the original author(s) and the source, pro-
vide a link to the Creative Commons license, and indicate if changes were
made.
References
1. Della Pepa R, Picardi M, Sora F, Stamouli M, Busca A, Candoni A,
Delia M, Fanci R, Perriello V, Zancanella M, Nosari A, Salutari P,
Marchesi F, Pane F, Pagano L, (2016) Successful management of
chronic disseminated candidiasis in hematologic patients treated with
high-dose liposomal amphotericin B: a retrospective study of the
SEIFEM registry. Supportive care in cancer : official journal of the
Multinational Association of Supportive Care in Cancer 24(9):3839–
3845. doi:10.1007/s00520-016-3208-0
2. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA,
Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA,
Walsh TJ, Zaoutis TE, Sobel JD (2016) Clinical practice guideline
for the management of candidiasis: 2016 update by the Infectious
Diseases Society of America. Clinical infectious diseases : an official
publication of the Infectious Diseases Society of America 62(4):e1–
50. doi:10.1093/cid/civ933
3. Vogelsinger H, Weiler S, Djanani A, Kountchev J, Bellmann-Weiler
R, Wiedermann CJ, Bellmann R (2006) Amphotericin B tissue dis-
tribution in autopsy material after treatment with liposomal
amphotericin B and amphotericin B colloidal dispersion. J
Antimicrob Chemother 57(6):1153–1160. doi:10.1093/jac/dkl141
4. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE,
Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA,
Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE,
Herbrecht R, HopeWW,Kibbler CC, Kullberg BJ,Marr KA,Munoz
P, Odds FC, Perfect JR, RestrepoA, RuhnkeM, Segal BH, Sobel JD,
Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE, European
Organization for R, Treatment of Cancer/Invasive Fungal Infections
Cooperative G, National Institute of A, Infectious Diseases Mycoses
Study Group Consensus G (2008) Revised definitions of invasive
fungal disease from the European Organization for Research and
Treatment of Cancer/Invasive Fungal Infections Cooperative Group
and the National Institute of Allergy and Infectious Diseases
Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical
infectious diseases : an official publication of the Infectious Diseases
Society of America 46(12):1813–1821. doi:10.1086/588660
5. Pagano L, Mele L, Fianchi L, Melillo L, Martino B, D'Antonio D,
Tosti ME, Posteraro B, Sanguinetti M, Trape G, Equitani F,
Carotenuto M, Leone G (2002) Chronic disseminated candidiasis
in patients with hematologic malignancies. Clinical features and out-
come of 29 episodes. Haematologica 87(5):535–541
6. Picardi M, Muretto P, De Rosa G, Selleri C, De Renzo A, Persico M,
Rotoli B (2002) Color ultrasound-guided fine needle cutting biopsy
for the characterization of diffuse liver damage in critical bone mar-
row transplanted patients. Haematologica 87(6):652–657
7. Common Terminology Criteria for Adverse Events (CTCAE) (2009)
Version 4.0 (May 28, 2009 (v4.03: June 14, 2010))
1046 Support Care Cancer (2017) 25:1045–1046
